Business, energy, technology, markets and global industry news from Business News Today

infantile-onset Niemann-Pick disease type C

PharmaDeviceNews infantile-onset Niemann-Pick disease type C
Representative image of a clinical researcher reviewing rare disease therapy data, as Beren Therapeutics faces an extended FDA decision timeline for adrabetadex in infantile-onset Niemann-Pick disease type C.
Pharma & Biotech

Why the FDA extended its adrabetadex review and what it means for Beren Therapeutics

Adrabetadex faces a longer FDA review in infantile-onset NPC. The delay could shape rare-disease drug standards in 2026.

Read More